Associations between regional adipose tissue distribution and skeletal muscle bioenergetics in older men and women.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101264860 Publication Model: Print Cited Medium: Internet ISSN: 1930-739X (Electronic) Linking ISSN: 19307381 NLM ISO Abbreviation: Obesity (Silver Spring) Subsets: MEDLINE
    • Publication Information:
      Publication: 2013- : Malden, MA : John Wiley & Sons
      Original Publication: Silver Spring, MD : NAASO, the Obesity Society, c2006-
    • Subject Terms:
      Energy Metabolism*/physiology ; Muscle, Skeletal*/metabolism ; Body Mass Index*; Humans ; Female ; Aged ; Male ; Cross-Sectional Studies ; Oxidative Phosphorylation ; Magnetic Resonance Imaging ; Adipose Tissue/metabolism ; Body Fat Distribution ; Mitochondria, Muscle/metabolism ; Intra-Abdominal Fat/metabolism ; Aged, 80 and over
    • Abstract:
      Objective: The aim of this study was to examine associations of ectopic adipose tissue (AT) with skeletal muscle (SM) mitochondrial bioenergetics in older adults.
      Methods: Cross-sectional data from 829 adults ≥70 years of age were used. Abdominal, subcutaneous, and visceral AT and thigh muscle fat infiltration (MFI) were quantified by magnetic resonance imaging. SM mitochondrial energetics were characterized in vivo ( 31 P-magnetic resonance spectroscopy; ATP max ) and ex vivo (high-resolution respirometry maximal oxidative phosphorylation [OXPHOS]). ActivPal was used to measure physical activity ([PA]; step count). Linear regression adjusted for covariates was applied, with sequential adjustment for BMI and PA.
      Results: Independent of BMI, total abdominal AT (standardized [Std.] β = -0.21; R 2  = 0.09) and visceral AT (Std. β = -0.16; R 2  = 0.09) were associated with ATP max (p < 0.01; n = 770) but not following adjustment for PA (p ≥ 0.05; n = 658). Visceral AT (Std. β = -0.16; R 2  = 0.25) and thigh MFI (Std. β = -0.11; R 2  = 0.24) were associated with carbohydrate-supported maximal OXPHOS independent of BMI and PA (p < 0.05; n = 609). Total abdominal AT (Std. β = -0.19; R 2  = 0.24) and visceral AT (Std. β = -0.17; R 2  = 0.24) were associated with fatty acid-supported maximal OXPHOS independent of BMI and PA (p < 0.05; n = 447).
      Conclusions: Skeletal MFI and abdominal visceral, but not subcutaneous, AT are inversely associated with SM mitochondrial bioenergetics in older adults independent of BMI. Associations between ectopic AT and in vivo mitochondrial bioenergetics are attenuated by PA.
      (© 2024 The Obesity Society.)
    • Comments:
      Update of: medRxiv. 2023 Nov 10:2023.11.10.23298359. doi: 10.1101/2023.11.10.23298359. (PMID: 37986822)
    • References:
      PLoS One. 2021 Jul 15;16(7):e0253849. (PMID: 34264994)
      Diabetes. 2002 Oct;51(10):2944-50. (PMID: 12351431)
      Am J Clin Nutr. 1999 Sep;70(3):405-11. (PMID: 10479203)
      Ageing Res Rev. 2009 Oct;8(4):339-48. (PMID: 19576300)
      J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):279-294. (PMID: 29368427)
      Biochim Biophys Acta. 2016 Apr;1862(4):716-724. (PMID: 26708941)
      Am J Physiol Endocrinol Metab. 2012 Dec 15;303(12):E1440-5. (PMID: 23047988)
      Mol Cell Endocrinol. 2013 Oct 15;379(1-2):30-4. (PMID: 23792186)
      Magn Reson Med. 2020 Dec;84(6):3146-3156. (PMID: 32519807)
      Methods. 2008 Dec;46(4):312-8. (PMID: 18930151)
      J Clin Endocrinol Metab. 2011 Feb;96(2):494-503. (PMID: 21106709)
      Am J Clin Nutr. 2009 Dec;90(6):1579-85. (PMID: 19864405)
      Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10771-8. (PMID: 7971961)
      Nutr Metab (Lond). 2022 May 21;19(1):37. (PMID: 35597962)
      Obesity (Silver Spring). 2013 Nov;21(11):2362-71. (PMID: 23512750)
      Am J Physiol Endocrinol Metab. 2021 Jul 1;321(1):E105-E121. (PMID: 33998291)
      Aging Cell. 2018 Apr;17(2):. (PMID: 29356348)
      Clin Nutr. 2006 Aug;25(4):573-80. (PMID: 16330136)
      Nat Rev Endocrinol. 2014 Nov;10(11):650-8. (PMID: 25200564)
      J Gerontol A Biol Sci Med Sci. 2023 Aug 2;78(8):1367-1375. (PMID: 36462195)
      BMC Public Health. 2013 May 06;13:449. (PMID: 23648225)
      Exp Mol Pathol. 2007 Aug;83(1):84-92. (PMID: 17239370)
      J Clin Invest. 2013 Mar;123(3):951-7. (PMID: 23454757)
      Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5618-23. (PMID: 15800038)
      Obesity (Silver Spring). 2021 Oct;29(10):1582-1595. (PMID: 34464025)
      Obesity (Silver Spring). 2019 Jul;27(7):1190-1199. (PMID: 31094076)
      Diabetes. 2008 Apr;57(4):987-94. (PMID: 18252894)
      Nature. 2006 Dec 14;444(7121):840-6. (PMID: 17167471)
      Am J Clin Nutr. 2013 Mar;97(3):552-60. (PMID: 23364001)
      J Clin Endocrinol Metab. 2010 Jun;95(6):2948-56. (PMID: 20382691)
      Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E49-58. (PMID: 19887598)
      J Gerontol A Biol Sci Med Sci. 2013 Apr;68(4):447-55. (PMID: 23051977)
      Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):511-7. (PMID: 20616711)
      Int J Obes Relat Metab Disord. 1999 Feb;23(2):126-32. (PMID: 10078845)
      Obes Facts. 2010 Dec;3(6):371-5. (PMID: 21196791)
      FASEB J. 1995 Feb;9(2):273-8. (PMID: 7781930)
      Med Sci Sports Exerc. 1982;14(1):101-2. (PMID: 7070249)
      Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):446-52. (PMID: 20585248)
      BMC Obes. 2015 Oct 06;2:40. (PMID: 26448868)
      Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1039-44. (PMID: 11052958)
      Int J Obes (Lond). 2005 Mar;29 Suppl 1:S36-9. (PMID: 15711582)
      J Gerontol A Biol Sci Med Sci. 2023 Oct 28;78(11):2083-2093. (PMID: 36754371)
      Endocr Rev. 2002 Apr;23(2):201-29. (PMID: 11943743)
      Nutrition. 2004 Mar;20(3):255-60. (PMID: 14990265)
    • Grant Information:
      P30 AG024827 United States AG NIA NIH HHS; R01 AG058883 United States AG NIA NIH HHS; R01 AG061805 United States AG NIA NIH HHS; R01 DK114012 United States DK NIDDK NIH HHS; U19 AG065188 United States AG NIA NIH HHS; R01 AG060499 United States AG NIA NIH HHS; I21 RX004409 United States RX RRD VA; R01AG066474 United States AG NIA NIH HHS; R01 AG073633 United States AG NIA NIH HHS; U01 AG060897 United States AG NIA NIH HHS; K01 AG059837 United States AG NIA NIH HHS; P30 AG021332 United States AG NIA NIH HHS; R01 AG054523 United States AG NIA NIH HHS; R01 AG059416 United States AG NIA NIH HHS; R01 AG066474 United States AG NIA NIH HHS; R01 AG072734 United States AG NIA NIH HHS; P30 AG068635 United States AG NIA NIH HHS; R01AG059416 United States AG NIA NIH HHS; I01 HX003518 United States HX HSRD VA; UL1 TR001420 United States TR NCATS NIH HHS; P30AG024827 United States AG NIA NIH HHS; UL1TR001420 United States TR NCATS NIH HHS; P30AG021332 United States AG NIA NIH HHS; United Kingdom WT_ Wellcome Trust; R01 AG077179 United States AG NIA NIH HHS
    • Publication Date:
      Date Created: 20240528 Date Completed: 20240528 Latest Revision: 20240927
    • Publication Date:
      20240927
    • Accession Number:
      PMC11139412
    • Accession Number:
      10.1002/oby.24008
    • Accession Number:
      38803308